Cargando…
Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ
BACKGROUND: Although treatment of ductal carcinoma in situ (DCIS) is controversial, national guidelines recommend considering endocrine therapy for women with estrogen receptor- (ER-) positive DCIS or those undergoing breast conserving surgery (BCS) without radiation. We evaluated uptake and predict...
Autores principales: | Anderson, Chelsea, Winn, Aaron N., Dusetzina, Stacie B., Nichols, Hazel B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615957/ https://www.ncbi.nlm.nih.gov/pubmed/29056966 http://dx.doi.org/10.1155/2017/6091709 |
Ejemplares similares
-
Tamoxifen Initiation After Ductal Carcinoma In Situ
por: Nichols, Hazel B., et al.
Publicado: (2016) -
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
por: Chen, Yunn-Yi, et al.
Publicado: (2009) -
Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic
por: Williams, Austin D., et al.
Publicado: (2021) -
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience
por: Levy, Julia, et al.
Publicado: (2022) -
ASO Visual Abstract: Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic
por: Williams, Austin D., et al.
Publicado: (2021)